Levitra (Generic Vardenafil 20mg)
Clinical guidance, bioequivalence criteria, and verified partner dispensing standards for Levitra (Generic Vardenafil 20mg). Reviewed by board-certified internal medicine and clinical pharmacotherapy specialists.
Levitra (Vardenafil) — Dosage Strengths & Online Availability
| Dosage Strength | Pack Supply | Dispensary Price | Stock Status | Verified Order |
|---|---|---|---|---|
| Levitra 10mg | Film-Coated Tablets • 30 / 60 Units | $2.04 / unit | ✓ In Stock (US Dispatch) | Select & Check Price ↗ |
| Levitra 20mg POPULAR | Film-Coated Tablets • 60 / 90 Units (Most Popular) | $1.28 / unitPOPULAR | ✓ In Stock (US Dispatch) | Select & Check Price ↗ |
| Levitra 40mg | Film-Coated Tablets • 90 / 180 Units (Best Value) | $0.68 / unitBEST VALUE | ✓ In Stock (US Dispatch) | Select & Check Price ↗ |
1. Clinical Dosing & Titration Protocols
Daily / Baseline Regimen
On-demand therapy only.
On-Demand / Titration Regimen
10mg to 20mg taken 30–60 minutes prior to intimacy.
Geriatric (>65) & moderate hepatic impairment: initiate at 5mg.
2. Patient Administration & Safe Usage Guidelines
Vardenafil is less sensitive to moderately fatty meals than sildenafil, making it a reliable on-demand choice.
Verified Telehealth Access Standards for Levitra (Generic Vardenafil 20mg)
Our clinical editorial board audits certified partner telehealth dispensaries to guarantee authentic WHO-GMP manufacturing, analytical batch testing, and physician-supervised asynchronous consultation.
Check Telehealth Protocol & Availability ↗3. Frequently Asked Patient Questions
Why is Levitra (Vardenafil) frequently prescribed for men with diabetes?
Diabetes impairs endothelial nitric oxide release. Vardenafil's extremely high molecular affinity (sub-nanomolar IC50 = 0.7 nM) allows it to maximize even trace amounts of NO, yielding an 72% success rate in diabetic clinical trials.
How does Vardenafil compare to Sildenafil?
Vardenafil is roughly 10 times more biochemically potent milligram-for-milligram than sildenafil and does not cause blue-tinted vision.
4. Pharmacological Mechanism & Receptor Profile
High-potency PDE5 inhibitor with 10x higher molecular binding affinity for PDE5 than sildenafil, displaying superior response rates in men with diabetes.
Urology & Men's Health • Levitra (Generic Vardenafil 20mg)
5. Chemical & Human Pharmacokinetic Matrix (Tmax, Half-Life, CYP450)
| Pharmacokinetic Parameter | Clinical Metric | Therapeutic Significance |
|---|---|---|
| Peak Plasma Time (Tmax) | 0.7 to 0.9 hour | Determines latency from ingestion to peak pharmacological onset. |
| Elimination Half-Life (T½) | 4.0 to 5.0 hours | Governs duration of action and steady-state dosing intervals. |
| Peak Concentration (Cmax) | 21 ug/L (20mg) | Maximum observed systemic concentration in human plasma. |
| Bioavailability & Food Interaction | 15% (high hepatic first-pass metabolism) | Defines oral bioavailability and dietary lipid dependency. |
| Plasma Protein Binding | 95% | Governs free circulating drug fraction available for receptor binding. |
| Volume of Distribution (Vd) | 208 Liters | Reflects tissue and lipid compartment penetration. |
| Hepatic Metabolism | Hepatic CYP3A4 and CYP3A5 | Primary enzymatic clearance and CYP pathways. |
| Elimination / Excretion | 95% feces, 5% urine | Renal vs biliary/fecal excretion balance. |
6. Drug-Drug Interaction Matrix
| Interacting Agent / Class | Severity Tier | Clinical Mechanism & Management Strategy |
|---|---|---|
| Nitrates | Contraindicated | Severe hypotension. |
| Class IA / III Antiarrhythmics (Amiodarone, Sotalol) | Precaution | QT interval prolongation. |
7. Adverse Reaction Profile & Clinical Incidence Rates
| Adverse Reaction | Incidence Rate | Physiological Mechanism & Mitigation Strategy |
|---|---|---|
| Headache | 15% | Cranial vasodilation. |
| Flushing | 11% | Facial erythema. |
| Nasal Congestion | 9% | Mucosal swelling. |
Peer-Reviewed Scientific Citations & FDA References
- Goldstein I, et al. Vardenafil for the treatment of erectile dysfunction in men with diabetes. Diabetes Care. 2003;26(3):777-783.